- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Partnering opportunities
- A complete cure for HBV
- A stable efficacious Toxoplasma vaccine
- Activating SMCHD1 to treat FSHD
- Improving vision outcomes in retinal detachment
- Intercepting inflammation with RIPK2 inhibitors
- Novel inhibitors for the treatment of lupus
- Novel malaria vaccine
- Precision epigenetics silencing SMCHD1 to treat Prader Willi Syndrome
- Rethinking CD52 a therapy for autoimmune disease
- Targeting minor class splicing
- Royalties distribution
- Start-up companies
- Partnering opportunities
- Collaborators
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- People
- Anne-Laure Puaux
- Associate Profesor Ian Majewski
- Associate Professor Aaron Jex
- Associate Professor Alyssa Barry
- Associate Professor Andrew Webb
- Associate Professor Chris Tonkin
- Associate Professor Daniel Gray
- Associate Professor Diana Hansen
- Associate Professor Edwin Hawkins
- Associate Professor Emma Josefsson
- Associate Professor Ethan Goddard-Borger
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Murphy
- Associate Professor James Vince
- Associate Professor Jason Tye-Din
- Associate Professor Jeanne Tie
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor Justin Boddey
- Associate Professor Kate Sutherland
- Associate Professor Leanne Robinson
- Associate Professor Marco Herold Marco Herold
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Matthew Ritchie
- Associate Professor Melissa Davis
- Associate Professor Misty Jenkins
- Associate Professor Nawaf Yassi
- Associate Professor Oliver Sieber
- Associate Professor Peter Czabotar
- Associate Professor Rachel Wong
- Associate Professor Rhys Allan
- Associate Professor Rosie Watson
- Associate Professor Ruth Kluck
- Associate Professor Sandra Nicholson
- Associate Professor Sant-Rayn Pasricha
- Associate Professor Seth Masters
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Wai-Hong Tham
- Associate Professor Wei Shi
- Catherine Parker
- Chela Niall
- Deborah Carr
- Dr Alisa Glukhova
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Brad Sleebs
- Dr Drew Berry
- Dr Gemma Kelly
- Dr Gwo Yaw Ho
- Dr Hui-Li Wong
- Dr Jacqui Gulbis
- Dr Joanna Groom
- Dr John Wentworth
- Dr Kelly Rogers
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Melissa Call
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Samir Taoudi
- Dr Shalin Naik
- Dr Sheau Wen Lok
- Dr Simon Chatfield
- Dr Stephen Wilcox
- Dr Tracy Putoczki
- Guillaume Lessene
- Helene Martin
- Joh Kirby
- Kaye Wycherley
- Keely Bumsted O'Brien
- Mr Joel Chibert
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Lew
- Professor Andrew Roberts
- Professor Anne Voss
- Professor Clare Scott
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Gabrielle Belz
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor Jane Visvader
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marc Pellegrini
- Professor Marnie Blewitt
- Professor Melanie Bahlo
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Burgess
- Professor Tony Papenfuss
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Undergraduate
- Student research projects
- A new regulator of stemness to create dendritic cell factories for immunotherapy
- Advanced methods for genomic rearrangement detection
- Control of cytokine signaling by SOCS1
- Defining the protein modifications associated with respiratory disease
- Delineating the pathways driving cancer development and therapy resistance
- Developing a new drug that targets plasmacytoid dendritic cells for the treatment of lupus
- Development and mechanism of action of novel antimalarials
- Development of a novel particle-based malaria vaccine
- Discovering novel therapies for major human pathogens
- Dissecting host cell invasion by the diarrhoeal pathogen Cryptosporidium
- Epigenetic biomarkers of tuberculosis infection
- Essential role of glycobiology in malaria parasites
- Evolution of haematopoiesis in vertebrates
- Human lung protective immunity to tuberculosis
- Identifying novel treatment options for ovarian carcinosarcoma
- Interaction with Toxoplasma parasites and the brain
- Interactions between tumour cells and their microenvironment in non-small cell lung cancer
- Investigating the role of mutant p53 in cancer
- Microbiome strain-level analysis using long read sequencing
- Minimising rheumatic adverse events of checkpoint inhibitor cancer therapy
- Modelling spatial and demographic heterogeneity of malaria transmission risk
- Naturally acquired immune response to malaria parasites
- Predicting the effect of non-coding structural variants in cancer
- Structural basis of catenin-independent Wnt signalling
- Structure and biology of proteins essential for Toxoplasma parasite invasion
- T lymphocytes: how memories are made
- TICKER: A cell history recorder for longitudinal patient monitoring
- Targeting host pathways to develop new broad-spectrum antiviral drugs
- Targeting post-translational modifications to disrupting the function of secreted proteins
- Targeting the epigenome to rewire pro-allergic T cells
- Targeting the immune microenvironment to treat KRAS-mutant adenocarcinoma
- The E3 ubiquitin ligase Parkin and mitophagy in Parkinson’s disease
- The molecular controls on dendritic cell development
- Understanding malaria infection dynamics
- Understanding the genetics of neutrophil maturation
- Understanding the neuroimmune regulation of innate immunity
- Understanding the proteins that regulate programmed cell death at the molecular level
- Using cutting-edge single cell tools to understand the origins of cancer
- When healthy cells turn bad: how immune responses can transition to lymphoma
- School resources
- Frequently asked questions
- Student profiles
- Abebe Fola
- Andrew Baldi
- Anna Gabrielyan
- Bridget Dorizzi
- Casey Ah-Cann
- Catia Pierotti
- Emma Nolan
- Huon Wong
- Jing Deng
- Joy Liu
- Kaiseal Sarson-Lawrence
- Komal Patel
- Lilly Backshell
- Megan Kent
- Naomi Jones
- Rebecca Delconte
- Roberto Bonelli
- Rune Larsen
- Runyu Mao
- Sarah Garner
- Simona Seizova
- Wayne Cawthorne
- Wil Lehmann
- Miles Horton
- Alexandra Gurzau
- Student achievements
- Student association
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- WEHI.TV
Cancer biology

Cancer occurs when cells develop changes that allow them to grow uncontrollably. Our cancer biology researchers are working to understand what causes these changes, how this leads to cancer, and what factors determine the success of cancer treatments. This is leading to better ways to diagnose and treat cancer.
Cancer biology research at the Institute
Our cancer researchers are discovering:
- The changes that make a normal cell become cancerous.
- The genes and proteins required for the growth and progression of cancer.
- New ways to treat cancer that target molecules essential for the cancer cell’s growth and survival.
- How to select the best treatment for a person with cancer.
How does cancer develop?
The growth of cells and tissues in the body is under tight control. This allows the body’s systems to work together. Sometimes it is important for certain cells or tissues to grow more than others. Examples of this are during the growth of a child, and the regrowth of tissue after an injury. There are many genes and proteins in cells that regulate cell growth in response to appropriate signals.
Cancer is initiated by a cell dividing uncontrollably. This is caused by changes to the genetic material (DNA) of the cell that alter the normal growth control genes and proteins. Cancer development is usually triggered after a single cell has acquired several changes that work together to drive cancer formation. Cancer cells typically contain higher-than-normal amounts of proteins that promote cancer growth. They also lack certain proteins that, in normal cells, limit growth.
Usually cancer-causing changes occur by chance (spontaneously). In some cases, cancer-causing genetic alterations are inherited from parents. Cancer-causing viruses can also introduce cancer-causing changes to cells. For example, the human papilloma virus (HPV) changes the DNA of cells in a woman’s cervix, which can lead to cervical cancer.
You can read more about the genes that are linked to cancer in our cancer page.
What makes a cancer cell?
Cancer cells have features that distinguish them from normal cells.
Normal cell |
Cancer cell |
Depends on external signals to divide |
Stimulates own division |
Limit on how many times it can divide (with the exception of stem cells) |
Can divide indefinitely |
Responds to ‘stop dividing’ signals from surrounding tissues |
Resists external ‘stop dividing’ signals |
Dies in response to internal and external signals |
Does not respond to cell death signals |
Blood vessel growth is tightly regulated into tissues |
Can stimulate growth of blood vessels into tumours |
Many processes that occur in cancer cells are also seen in normal cells. The difference between cancer cells and normal cells is how these processes are controlled. It is the improper regulation of cell division, cell death and blood vessel growth that drives cancer formation.
The features of cancer cells are caused by abnormalities in specific proteins. These abnormalities can be either an excess amount of, or a lack of, a particular protein. In some cancers, the way a protein functions, called its activity, can be changed. This is often caused by changes, called mutations, to the gene giving instructions for making the protein.
Developing treatments for cancer
Cancer is treated either by halting the growth of the cancer cells, by killing the cancer cells within the body, or by surgically removing them. If all the cells in a cancer are not completely killed or removed, there is a risk that the cancer will ‘recur’ or ‘relapse’.
Understanding how changes in genes and proteins give cells cancer-like features is leading to new treatments for cancer. Potential new anti-cancer agents are being developed that block the function of the proteins that allow cancer cell growth.
Related information:
- Medicinal chemistry: how basic cancer research can be used to develop potential new anti-cancer treatments.
- Immunotherapy: our researchers are working on an innovative form of immunotherapy that harnesses the body’s own immune cells to kill cancer cells.
- Cliinical translation: how our cancer discoveries are being translated into better treatments for patients.
Matching cancer patients to treatments
Every human cancer has developed because of unique changes to genes and proteins. Even two people’s cancers that have arisen from the same cell type can be very different at a molecular level.
These molecular differences can influence:
- How quickly the cancer grows.
- Whether, and where the cancer cells spread around the body (metastasise).
- How well the cancer responds to different treatments.
- Whether the cancer will come back (relapse) after treatment.
Our researchers are determining how people with cancer can be matched to the best treatment for their individual disease. You can read more about this on our personalised medicine page.
Researchers:
Australian cancer researchers will gain access to first-in-Australia technology through new funding from the Australian Cancer Research Foundation
A signalling molecule called interleukin-11 is a potential new target for anti-cancer therapies
Joan Heath and colleagues discovered a genetic defect that can halt cell growth and force cells into a death-evading survival state.